[
  {
    "title": "Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial",
    "year": 2015,
    "study_type": "Randomized controlled clinical trial",
    "population": "Adults with active rheumatoid arthritis",
    "results_summary": "This randomized controlled clinical trial evaluated tripterygium wilfordii hook f in adults with active rheumatoid arthritis. Results showed that non-inferiority to methotrexate with highest responses in combination therapy; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial.” PubMed, 2015, https://pubmed.ncbi.nlm.nih.gov/24733191/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24733191/"
  },
  {
    "title": "Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial",
    "year": 2009,
    "study_type": "Randomized controlled trial",
    "population": "Adults with active rheumatoid arthritis",
    "results_summary": "This randomized controlled trial evaluated tripterygium wilfordii hook f extract in adults with active rheumatoid arthritis. Results showed that higher ACR responses than sulfasalazine with gastrointestinal adverse events; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.” PubMed, 2009, https://pubmed.ncbi.nlm.nih.gov/19687490/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/19687490/"
  },
  {
    "title": "Efficacy and safety of Tripterygium wilfordii Hook F plus TNF receptor fusion protein in active rheumatoid arthritis",
    "year": 2023,
    "study_type": "Randomized double-blind triple-dummy controlled trial",
    "population": "Adults with active rheumatoid arthritis",
    "results_summary": "This randomized double-blind controlled trial evaluated tripterygium wilfordii hook f added to TNF receptor fusion protein in adults with active rheumatoid arthritis. Results showed that increased ACR50 responses compared with monotherapy with acceptable safety; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Efficacy and safety of Tripterygium wilfordii Hook F plus TNF receptor fusion protein in active rheumatoid arthritis.” PubMed, 2023, https://pubmed.ncbi.nlm.nih.gov/37657525/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37657525/"
  },
  {
    "title": "Predicting and verifying outcome of Tripterygium wilfordii Hook F therapy in rheumatoid arthritis",
    "year": 2015,
    "study_type": "Two-stage clinical trial",
    "population": "Adults with rheumatoid arthritis",
    "results_summary": "This two-stage clinical trial evaluated tripterygium wilfordii hook f therapy in adults with rheumatoid arthritis. Results showed that baseline predictors identified and verified for treatment response; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Predicting and verifying outcome of Tripterygium wilfordii Hook F therapy in rheumatoid arthritis.” PubMed, 2015, https://pubmed.ncbi.nlm.nih.gov/26814847/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26814847/"
  },
  {
    "title": "Meta‑Analysis of Clinical Efficacy and Safety of Tripterygium Glycosides in Chronic Kidney Disease",
    "year": 2021,
    "study_type": "Systematic review and meta-analysis of randomized trials",
    "population": "Adults with chronic kidney disease",
    "results_summary": "This systematic review and meta-analysis of randomized trials evaluated tripterygium glycosides in adults with chronic kidney disease. Results showed that reduced proteinuria and improved albumin with mixed safety signals; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Meta‑Analysis of Clinical Efficacy and Safety of Tripterygium Glycosides in Chronic Kidney Disease.” PubMed, 2021, https://pubmed.ncbi.nlm.nih.gov/34093720/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34093720/"
  },
  {
    "title": "Tripterygium wilfordii Hook F for primary nephrotic syndrome: systematic review",
    "year": 2013,
    "study_type": "Systematic review and meta-analysis",
    "population": "Adults with primary nephrotic syndrome",
    "results_summary": "This systematic review and meta-analysis evaluated tripterygium wilfordii hook f in adults with primary nephrotic syndrome. Results showed that add-on benefit for remission with low trial quality; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Tripterygium wilfordii Hook F for primary nephrotic syndrome: systematic review.” PubMed, 2013, https://pubmed.ncbi.nlm.nih.gov/23934958/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23934958/"
  },
  {
    "title": "Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis",
    "year": 2009,
    "study_type": "Meta-analysis of randomized and quasi-randomized trials",
    "population": "Adults with idiopathic refractory nephrotic syndrome",
    "results_summary": "This meta-analysis evaluated tripterygium wilfordii hook f in adults with idiopathic refractory nephrotic syndrome. Results showed that increased remission rates versus control in pooled analyses; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis.” PubMed, 2009, https://pubmed.ncbi.nlm.nih.gov/19287181/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/19287181/"
  },
  {
    "title": "Meta-analysis of Tripterygium wilfordii Hook F in the treatment of IgA nephropathy",
    "year": 2010,
    "study_type": "Meta-analysis of randomized clinical trials",
    "population": "Adults with IgA nephropathy",
    "results_summary": "This meta-analysis of randomized clinical trials evaluated tripterygium wilfordii hook f in adults with IgA nephropathy. Results showed that higher remission and reduced proteinuria versus controls; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Meta-analysis of Tripterygium wilfordii Hook F in the treatment of IgA nephropathy.” PubMed, 2010, https://pubmed.ncbi.nlm.nih.gov/20930429/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20930429/"
  },
  {
    "title": "Tripterygium wilfordii, a Chinese herb effective in male antifertility",
    "year": 1987,
    "study_type": "Review with clinical observations",
    "population": "Men exposed to Tripterygium wilfordii",
    "results_summary": "This review evaluated tripterygium wilfordii in men exposed to therapeutic doses. Results showed that antifertility effects with decreased sperm motility and count with reversibility after discontinuation; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Tripterygium wilfordii, a Chinese herb effective in male antifertility.” PubMed, 1987, https://pubmed.ncbi.nlm.nih.gov/3315438/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/3315438/"
  },
  {
    "title": "Immunosuppressive treatment for idiopathic membranous nephropathy: updated systematic review",
    "year": 2014,
    "study_type": "Systematic review",
    "population": "Adults with idiopathic membranous nephropathy",
    "results_summary": "This systematic review evaluated tripterygium wilfordii evidence within immunosuppressive regimens in adults with idiopathic membranous nephropathy. Results showed that evidence too sparse to draw conclusions compared with standard regimens; mostly minor adverse events reported. Effects were generally modest and safety signals were acceptable, but larger and longer trials are recommended.",
    "mla_citation": "“Immunosuppressive treatment for idiopathic membranous nephropathy: updated systematic review.” PubMed, 2014, https://pubmed.ncbi.nlm.nih.gov/25318831/. Accessed 24 Oct. 2025.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25318831/"
  }
]